Using Fosfomycin to Treat Bacterial Infections
Use of Fosfomycin in the Treatment of Bacterial Infections: "real-life" Study At the ASST of Lecco
This study looks at how well the antibiotic fosfomycin works and how safe it is for hospitalized patients with bacterial infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Azienda Ospedaliera di Lecco Academic / other |
| Locations | 1 site (Lecco, Lecco) |
| Trial ID | NCT06814899 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes medical records of patients treated with intravenous fosfomycin at ASST Lecco from April 2020 to December 2023. Fosfomycin is a bactericidal antibiotic effective against a wide range of Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. The study aims to evaluate the effectiveness and safety of fosfomycin in hospitalized patients, focusing on its distribution in various tissues and its anti-biofilm properties.
Who should consider this trial
Good fit: Ideal candidates are hospitalized patients over 18 years old who have been treated with intravenous fosfomycin for at least 72 hours.
Not a fit: Patients who received fosfomycin IV for less than 72 hours or who experienced adverse events may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the effectiveness of fosfomycin for treating complex bacterial infections, potentially improving patient outcomes.
How similar studies have performed: While fosfomycin has been used in clinical settings, this specific observational approach to analyze its effectiveness in a defined patient population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years; * Patients hospitalized at A. Manzoni Lecco between April 2020 and December 2023; * Patients treated with IV fosfomycin as monotherapy or in combination with other antibiotics for at least 72 hours. Exclusion Criteria: * Patients who received fosfomycin IV for less than 72h for any cause (death, adverse events, clinical decision).
Where this trial is running
Lecco, Lecco
- Stefania Piconi — Lecco, Lecco, Italy (Recruiting)
Study contacts
- Study coordinator: Stefania Piconi, MD
- Email: s.piconi@asst-lecco.it
- Phone: +390341489890
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.